AWAlan J. Wein

Alan J. Wein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alan J. Wein has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Response to Letter to the Editor on “Unveiling ‘Idiopathic’ Nocturia: The Central Role of Sleep‐Induced Hypogonadism and ANP‐Mediated Hemodynamics”

    by Qi‐Xiang Song, Sanjay Sinha, Bahareh Vahabi, Anthony Kanai, Christopher Fry, Pradeep Tyagi, Stefania Musco, Dudley Robinson, Marcus J. Drake, Paul Abrams, et al.

  • Open Access

    How Can We Improve the Assessment and Indifferent Outcomes From Pelvic Organ Prolapse Management From Conservative and Surgical Therapies? ICI‐RS 2025

    by Rohna Kearney, Adrian Wagg, Wendy Bower, Chris Chapple, Vik Khullar, Dudley Robinson, Annika Taithongchai, Philip Toozs Hobson, Alan Wein, Paul Abrams

    Introduction: Pelvic organ prolapse is a common condition and many women seek surgical treatment for prolapse symptoms. However, recurrence of prolapse after surgical treatment is common. A think tank was held at ICI‐RS 2025 to discuss how the assessment and indifferent results from conservative and surgical management can be improved. Methods: Data were collected and presented on identification of women at risk of prolapse recurrence after surgery, understanding patient goals and expectations, optimising lifestyle interventions, pelvic floor muscle training, pessary management, and surgical care. Discussions identified knowledge gaps and proposed research studies that could advance knowledge to improve treatment outcomes. Results: There is insufficient information to understand the assessment of prolapse treatment outcomes; examination findings do not necessarily correlate with symptoms. Further research is needed to understand if patient‐reported goal attainment is superior to patient‐reported outcome measures, including measures of patient satisfaction. There is insufficient information on the value of lifestyle adjustments and pelvic floor muscle training as prehabilitation to improve surgical outcomes. The place of pessary management in an optimally integrated prolapse treatment pathway is unclear and the role that pessaries may have in anatomical modelling of prolapse is not fully understood. Further research into adjuncts to improve native tissue repair as alternatives to polypropylene mesh is needed to optimise surgical outcome. Conclusion: Further research into understanding what represents treatment, cure, and optimising conservative and surgical treatments is of high priority to improve pelvic organ prolapse treatment outcomes. The utility of preoperative rehabilitation requires investigation. Developing an optimised pessary care pathway and continued surgical innovation are required to ensure progress in reducing prolapse symptom recurrence.


  • Open Access

    Correction to: Primer on Urology

    by Christopher R. Chapple, Alan J. Wein

  • Are There Potential New Therapeutic Avenues for Treating Idiopathic Nocturia? ICI‐RS 2025

    by Qi‐Xiang Song, Sanjay Sinha, Bahareh Vahabi, Anthony Kanai, Christopher Fry, Pradeep Tyagi, Stefania Musco, Dudley Robinson, Marcus J. Drake, Paul Abrams, et al.

    Background: Nocturia is a prevalent condition with systematic etiologies which require multidisciplinary collaborations during diagnosis and management. Here we evaluate current evidence and present unresolved research questions regarding the three key pathophysiological domains of nocturia with respect to a conceptual brain‐kidney‐bladder axis, namely sleep enhancement, extra‐renal water reabsorption and circadian regulation of bladder tissue. Methods: A Think Tank was convened at the 12th International Consultation on Incontinence Research Society meeting in June 2025, looking at novel therapeutic targets for nocturia. This article synthesizes key deliberations from this meeting session. Results: The discussion was mainly focused on idiopathic nocturia with an overactive bladder symptom complex or nocturnal polyuria. Firstly, medications and conservative nondrug measures targeting sleep that could potentially improve nocturia were considered. Secondly, investigation of water reabsorption mechanisms within the bladder and the role of small molecule vasopressin receptor type‐2 agonists were examined that may provide novel therapeutic options to rectify nocturnal polyuria. Finally, to address circadian misalignments, organ specific chronotherapies, based on abnormal circadian features of bladder tissues that can be curative for nocturia, were discussed. Conclusions: The evidence indicates that promising therapeutic modalities targeting the regulation of sleep‐wake cycles, intravesical water transport mechanisms, and circadian patterns of detrusor activity may offer alternative strategies for managing nocturnal polyuria. However, further mechanistic investigations and randomized controlled trials are required to advance these approaches toward clinical translation.


  • Open Access

    Phenotyping Overactive Bladder—Part 1: Are There Different Types of Urgency and Can They be Translated to Clinical, Urodynamic and Radiological Phenotyping? ICI‐RS 2025

    by John E. Speich, D. Carolina Ochoa, Pradeep Tyagi, Apostolos Apostolidis, Sanjay Sinha, Claire Hentzen, Marcus Drake, Paul Abrams, Alan J. Wein, Michel Wyndaele

    Introduction: Overactive bladder (OAB) is defined as urinary urgency, usually accompanied by increased daytime frequency and/or nocturia, with urgency urinary incontinence (OAB‐wet) or without (OAB‐dry), in the absence of urinary tract infection or other detectable disease. The key symptom of OAB, urinary urgency, is defined as a complaint of sudden, compelling desire to pass urine which is difficult to defer. However, patients report a range of individual experiences and sensations associated with urgency and studies have identified different types of urgency. Patients with OAB not only differ in clinical presentation, but also have different urodynamic and radiological findings. These variations may explain why OAB treatments work well for some individuals but not others. This paper investigates how knowledge can be advanced by phenotyping OAB by urgency symptom variation, and clinical, urodynamic measurements and radiological features. Methods: A Think Tank at the International Consultation on Incontinence‐Research Society (ICI‐RS) 2025 discussed the question, “Can OAB management be improved by phenotyping if there are different types of urgency?” The group discussed the current literature on this topic and developed a list of research questions to help shape the future of the field. Results: Clinical, urodynamic and radiological phenotyping of urgency were discussed and research studies to phenotype urgency were proposed. Conclusion: Further research to phenotype OAB beyond the presence or absence of urgency and urgency urinary incontinence, using clinical, urodynamic measurements and radiological features, is needed. High priority research questions and strategies were defined. Advanced OAB phenotyping may guide tailored management beyond a stepwise approach, with the aim to improve therapeutic outcomes. This would validate phenotyping and is explored in Part 2 of the topic.


  • How Can We Make Progress in the Management of Bladder Pain Syndrome? ICI‐RS 2025

    by Sachin Malde, Sanjay Sinha, Roger Dmochowski, Michael Samarinas, Pradeep Tyagi, D. Carolina Ochoa, Caroline Selai, Ana Charrua, Alan J. Wein, Paul Abrams

    Aims: Management algorithms for Bladder Pain Syndrome (BPS) have remained stagnant over the past 20 years. Lack of high level evidence has hindered progress. Contributors to this have been the use of confusing and inconsistent terminology and failure to adequately phenotype participants entering clinical trials. At the International Consultation on Incontinence Research Society (ICI‐RS) meeting in 2025 a Think Tank addressed the question of “How can we make progress in the management of Bladder Pain Syndrome,” focussing on the non‐Hunner lesion group. Methods: The Think Tank conducted a literature review and expert consensus meeting focusing on the current limitations in terminology and phenotyping, how we can improve identification of bladder‐centric BPS, and how we can improve assessment of psychological comorbidity. Results: Terminology needs to be standardised to enable more homogenous recruitment to clinical trials. Use of the term “interstitial cystitis” may be misleading, and the term is often inappropriately used. Classification based on the European Association of Urology guidelines should be favoured, using the term Primary Bladder Pain Syndrome. Participants entering clinical trials need to undergo thorough investigation to enable accurate phenotyping. The non‐Hunner lesion BPS group need to be the focus of future research. Tools to aid identification of a bladder‐centric phenotype (through biopsy and other techniques) need to be studied, including investigating the roles of inflammation, ischaemia and oxidative stress in this condition. A psychological assessment tool specific for BPS should be created to ensure earlier psychological intervention for those who would benefit most. Conclusions: The use of accurate terminology in describing this condition is the first step toward improving the quality of future research. The Think Tank overwhelmingly recommended that the term “Interstitial Cystitis” should not be used. Future studies should be focussed on understanding the BPS group, excluding those with Hunner lesion disease. Studying inflammation, ischaemia and oxidative stress will help to identify a bladder‐centric phenotype, whereas improving our understanding of psychological mechanisms will help to direct psychological therapies more effectively.


  • How Could the Proposed International Continence Society (ICS) Global Urodynamics Data Repository (GUDRep) Demonstrate the Clinical Role and Cost Effectiveness of Urodynamics in Individual Patients? ICI‐RS 2025

    by Enrico Finazzi Agrò, Daniele Bianchi, Riccardo Lombardo, Kevin Rademakers, Angie Rantell, Eric S. Rovner, John E. Speich, Tufan Tarcan, Glenn T. Werneburg, Hashim Hashim, et al.

    Introduction: The management and interpretation of big data appears to be an increasingly attractive but challenging issue in functional urology. The International Continence Society (ICS) Global Urodynamics (UDS) Data Repository (GUDRep) project aims to record and analyse UDS data to share research and clinical information about UDS. Objectives: The aim of this Think Tank was to identify the main research questions and critical issues related to the GUDRep project. Methods: This article reports and summarises the discussions on the GUDRep from the 2025 meeting of the International Consultation on Incontinence‐Research Society (ICI‐RS). Results and Conclusions: Several research questions on the GUDRep project need to be considered, including both issues/barriers in building the Repository and economic, clinical and research advantages which could potentially be obtained by the GUDRep itself.


  • Is There Evidence of Diagnostic and Treatment Gaps for LUTS in Post‐Menopausal Women With Genitourinary Syndrome of the Menopause? ICI‐RS 2025

    by Apostolos Apostolidis, Ana Sofia Da Silva, Thomas Gray, Vik Khullar, Rayan Mohamed‐Ahmed, Efstathios Papaefstathiou, Mauro Van Den Ende, Alan Wein, Paul Abrams, Dudley Robinson

    Aims: This report, from the International Consultation on Incontinence‐Research Society, aims to evaluate the existing evidence and identify diagnostic and treatment gaps for Lower Urinary Tract Symptoms (LUTS) in post‐menopausal women with Genitourinary Syndrome of Menopause (GSM). Methods: An overview on the current literature, including pathophysiology, diagnosis and management of GSM associated LUTS, including incontinence, overactive bladder, underactive bladder and recurrent urinary tract infections (rUTIs). Results: Significant gaps in the literature were identified. GSM is underdiagnosed and the interplay between hormonal changes in the postmenopausal period on LUTS remains poorly understood. Diagnostic methods for rUTIs lack sensitivity and the role of the urinary microbiome is emerging. Current treatments, including topical oestrogens and systemic hormone therapy, lack long‐term efficacy data on LUTS. Evidence for regenerative medicine techniques remain limited by low‐quality studies and short‐term follow up. Conclusion: There is lack of high‐quality evidence, which hinders the optimal management of LUTS in post‐menopausal women with GSM. The panel proposes targeted research questions, focusing on the hormonal impact on the lower urinary tract, advancing diagnostics and robust clinical trials for existing and novel therapies, to bridge current gaps in the literature and improve patient care.


  • Measurement of Oxidative Stress to Allow the Development and Use of New Therapies in Lower Urinary Tract Dysfunction: ICI‐RS 2025

    by Tufan Tarcan, Bahareh Vahabi, Giovanni Mosiello, Christopher Fry, Pradeep Tyagi, Donna Sellers, Riccardo Lombardo, Alan Wein, Paul Abrams, Anthony Kanai

    Aims: Evaluate current knowledge of the physiological and clinical consequences of oxidative stress on the development of lower urinary tract dysfunction (LUTD), identify clinically relevant biomarkers and potential therapeutics. Methods: This review summarizes topics discussed during Proposal #7 at the International Consultation on Incontinence Research Society 2025 meeting and derives a consensus of future research directions. Results: Pelvic ischemia/hypoxia can result in LUTD including detrusor over‐/underactivity, bladder pain syndrome and nocturia. Major causes of bladder ischemia include aging, atherosclerosis and bladder outlet obstruction. The bladder wall undergoes physiological cycles of ischemia and reperfusion with normal filling and emptying: thus, infrequent voiding habits, co‐morbidities and some medications can exacerbate LUTD. Ischemia can lead to oxidative stress which is an increase in reactive oxygen species (ROS), superoxide and the hydroxyl radical, over enzymatic antioxidants, superoxide dismutase and glutathione peroxidase. ROS can be generated by monoamine, xanthine and nicotinamide adenine dinucleotide phosphate oxidases, but the main source is dysfunctional mitochondria. Biomarkers of oxidative stress such as 8‐hydroxydeoxyguanosine, indicative of DNA damage, can be measured in plasma and urine. Soluble guanylate cyclase activators have been recently demonstrated to have beneficial actions in several LUTD by ameliorating prostatic hyperplasia, bladder overactivity, cellular senescence and fibrosis. Conclusion: Many LUTD were identified as having links to oxidative stress. There are still questions regarding correlation of the severity of oxidative stress to LUTD symptomology, the selectivity of biomarkers and the most efficacious druggable target. These were considered key research directions for future studies.


  • Open Access

    Phenotyping Overactive Bladder – Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI‐RS 2025

    by Michel Wyndaele, Michael Samarinas, Apostolos Apostolidis, D. Carolina Ochoa, Giovanni Mosiello, Brigitte Schurch, Pradeep Tyagi, Alan Wein, Paul Abrams, John E. Speich

    Introduction: Management of overactive bladder (OAB) has a stepwise approach in adults and children. This does not account for individual patient variations, which may explain suboptimal outcomes in many patients. Distinct OAB profiles, based on patient characteristics, symptoms, urodynamic findings and imaging have been discussed in Part 1. Personalized treatment and escalation pathways based on OAB profiling may lead to faster OAB symptom control and quality of life improvement, reduced cumulative side effects and costs, and improved treatment adherence. Methods: A Think Tank at the International Consultation on Incontinence‐Research Society (ICI‐RS) 2025 discussed the question, “Can OAB management be improved by phenotyping, and targeting therapy according to urgency type and other characteristics?” The group discussed the current literature on this topic and developed a list of research questions and strategies to help shape the future of the field. Results: Tailored combination of antimuscarinics and/or beta3 agonists, with botulinum toxin A (BTX‐A) and/or sacral nerve stimulation (SNS) was considered a high priority research topic. Profile‐based individual treatment selection and delivery protocols for BTX‐A and SNS are potential means to improve outcomes, as is the early escalation to BTX‐A and SNS in the treatment pathway of both adults and children. Finally, phenotype‐based treatment requires tight treatment outcome follow‐up and possible adjustment (including re‐phenotyping) for which tools need to be developed. Conclusion: Development and validation of a patient‐based flow‐chart to replace the current stepwise approach in OAB management will allow tailored treatment, aimed to improve therapeutic success, and to reduce side effects.